The proposed $2,400,000 settlement covers people and entities that purchased or otherwise acquired Revance Therapeutics securities between February 29, 2024 and the close of the company's merger with Crown Laboratories on February 6, 2025. Payment is a pro rata share of the net settlement fund allocated by recognized losses, and a Proof of Claim and Release Form - including the documents the form asks for - must be postmarked or filed online by March 17, 2027. The settlement hearing is December 17, 2026, and the court has not yet given final approval.
Benefit Summary
Eligible class members: available benefits include Pro rata fund share.
Payments come from the $2,400,000.00 settlement fund and may change after approved deductions.
Available Awards
Pro rata fund share
Who Is Included
Former record or beneficial holders of Revance common stock at the February 6, 2025 merger closing who received $3.65 per share and acquired their shares before February 29, 2024, or acquired them from February 29, 2024 through February 6, 2025 but are not eligible for compensation for those shares under the separate Revance federal securities settlement. The notice lists exclusions for the defendant, Crown, certain officers and directors, related family members and accounts, and other associated persons or entities.
- Products included: Revance Therapeutics common stock exchanged for $3.65 per share in the February 6, 2025 Crown Laboratories merger.
- Purchase window: Shares acquired before February 29, 2024, or qualifying shares acquired from February 29, 2024 through February 6, 2025 that are not compensated by the separate securities settlement.
- Proof required: Submit the Proof of Claim and the documents that form requests to establish eligible Revance shareholdings. The notice does not list the precise documents in its text.
Claim and Payment Information
- Claim method: Online or mail
- Claim deadline: 2027-03-17
- Instructions: Complete the Proof of Claim, include the documents requested by that form, and submit it online or mail it with a postmark no later than March 17, 2027.
Questions & Answers
Who is included in the Revance settlement?
The class generally covers former Revance common stockholders at the February 6, 2025 merger closing who received $3.65 per share and acquired their shares before February 29, 2024, or acquired them from February 29, 2024 through the closing but are not eligible for payment for those shares from the separate federal securities settlement.
How does the separate Revance securities settlement affect eligibility?
Shares acquired from February 29, 2024 through February 6, 2025 are included here only to the extent they are not eligible for compensation under the separate federal securities settlement. The notice excludes those shares, and claims tied to them, when the federal settlement covers them.
What payment could an eligible claimant receive?
Approved claims share the Net Settlement Fund in proportion to eligible Revance stock holdings. The notice does not promise a fixed amount per share. The final amount depends on approved deductions and the eligible shares claimed by everyone, and calculated distributions below $10 are not paid.
How do I submit a claim?
Submit the Proof of Claim online through the settlement website, or mail the completed form with the documents it requests. Online claims must be received and mailed claims must be postmarked by March 17, 2027.
What proof is required?
The notice says to include all documents requested by the Proof of Claim. It does not identify the precise supporting documents in the notice text, so follow the form’s instructions for proving eligible shareholdings.
Can I opt out of this settlement?
No. The Court preliminarily certified a non-opt-out class, so class members cannot exclude themselves. A class member who does nothing receives no payment but remains bound if the settlement becomes effective.
How can I object, and when is the hearing?
Written objections and requests to speak must be filed and served as the notice directs by December 3, 2026. The settlement hearing is scheduled for December 17, 2026 at 11:00 a.m. in Wilmington, Delaware, or remotely by Zoom if the Court chooses.
When would payments be sent?
Payments cannot be distributed until the Court approves the settlement and allocation plan, the settlement becomes effective, and any appeals are resolved. The notice does not give a payment date.
Does the notice contain any date typography issues?
Yes. The PDF repeats the year in two places, printing “August 7, 2026, 2026” for the stipulation and “December 17, 2026, 2026” in one hearing paragraph. Its summary table and the rest of the hearing section consistently identify the hearing as December 17, 2026.
Other Important Dates
- Objection deadline: 2026-12-03
- Final approval hearing: December 17, 2026, at 11:00 a.m.
- Hearing location: Court of Chancery of the State of Delaware, Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801, or remotely by Zoom in the Court’s discretion
Case Details
- Total settlement fund: $2,400,000.00
- Case name: Dena A. Gilmore v. Mark J. Foley; Seane Jones v. Mark J. Foley
- Case number: C.A. Nos. 2025-1415-NAC and 2026-0177-NAC
- Court: Court of Chancery of the State of Delaware
- Administrator: RG/2 Claims Administration, LLC
- Official Settlement Website: https://www.rg2claims.com/revance.html
Sources
Claim form, FAQ, deadlines, administrator information
Court-approved notice describing eligibility and benefits